XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.22.2

Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 10, 2022 USD ($) | Jun. 24, 2020 | Jun. 30, 2017 USD ($) | Jun. 30, 2017 EUR (€) | Apr. 30, 2022 USD ($) | Aug. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Feb. 10, 2022 | Dec. 16, 2021 USD ($) | Dec. 16, 2021 EUR (€) | Jul. 26, 2021 | Jul. 08, 2021 shares | Dec. 01, 2020 USD ($) | Apr. 26, 2019
Collaborative Arrangement, Payment for Research and Development Agreement |  |  | $ 1,100,000 | € 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  |  | $ 658,553 |  | $ 937,092 | $ 1,306,980 | $ 1,397,612 |  |  |  |  |  |  |  |
Number of Performance Obligations |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 | 2 |  |  |  |
Upfront Payment Payable |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |
Research and Development Expense, Related Party |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |
Deferred License Revenue, Current |  |  |  |  |  |  | 176,471 |  |  | 176,471 |  | 147,059 |  |  |  |  |  |  |
Deferred License Revenue, Net of Current Portion |  |  |  |  |  |  | 264,706 |  |  | 264,706 |  | $ 352,941 |  |  |  |  |  |  |
Cost of Goods and Services Sold, Total |  |  |  |  |  |  | 411,109 |  | 829,504 | 815,855 | 1,220,266 |  |  |  |  |  |  |  |
Research and Development Expense, Total |  |  |  |  |  |  | 1,830,798 |  | 2,209,242 | 3,173,660 | 4,017,340 |  |  |  |  |  |  |  |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Sales of Business, Affiliate and Productive Assets |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  |  |  | € 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sale of Stock, Percentage of Ownership after Transaction |  | 2.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novovet [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00%
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment Owned, Balance, Shares (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 129,661 |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.37% |  |
Cost of Goods and Services Sold, Total |  |  |  |  |  |  | 0 |  |  | 109,000 |  |  |  |  |  |  |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.99% |
Equity Securities without Readily Determinable Fair Value, Amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 284,709 |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.10% |  |  |
Research and Development Expense, Total |  |  |  |  |  |  | 0 |  |  | 0 |  |  |  |  |  |  |  |  |
BDI Holdings [Member] | Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  |  | 16.10% | 16.10% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  | € 936,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
VLPBio Member |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.30% |  |  |
VLPBio Member | Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  |  | 3.30% | 3.30% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  |  | 614,435 |  | 937,092 | 1,148,156 | 1,397,612 |  |  |  |  |  |  |  |
License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  |  | 44,118 |  | $ 0 | 158,824 | $ 0 |  |  |  |  |  |  |  |
A Global Food Ingredient Company [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | $ 4,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
A Global Food Ingredient Company [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  |  | 113,000 |  |  | 113,000 |  |  |  |  |  |  |  |  |
Abic Biolgical Latories Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Performance Obligations |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
Abic Biolgical Latories Ltd. [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  |  | 40,000 |  |  | 54,000 |  |  |  |  |  |  |  |  |
Abic Biolgical Latories Ltd. [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  | $ 100,000 |  | 0 | $ 100,000 |  | 100,000 |  |  |  |  |  |  |  |  |
Janssen Pharmaceutical Companies [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable Upfront Payment, Received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |
Deferred License Revenue, Current |  |  |  |  |  |  | 176,000 |  |  | 176,000 |  |  |  |  |  |  |  |  |
Deferred License Revenue, Net of Current Portion |  |  |  |  |  |  | 265,000 |  |  | 265,000 |  |  |  |  |  |  |  |  |
Deferred License Revenue |  |  |  |  |  |  | 44,000 |  |  | 59,000 |  |  |  |  |  |  |  |  |
Janssen Pharmaceutical Companies [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax |  |  |  |  |  |  | $ 181,000 |  |  | $ 246,000 |  |  |  |  |  |  |  |  |
Contract with Customer, Asset, after Allowance for Credit Loss, Total | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 1,600,000 |  |  |  |

X
- Definition Represents duration of agreement for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents equity interest acquired for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents minimum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payment for research and development agreement for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents deferred license revenue. + References No definition available. + Details
Name: | dyai_DeferredLicenseRevenue
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents current deferred license revenue. + References No definition available. + Details
Name: | dyai_DeferredLicenseRevenueCurrent
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents net of current portion related to deferred license revenue. + References No definition available. + Details
Name: | dyai_DeferredLicenseRevenueNetOfCurrentPortion
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents ownership percentage by noncontrolling owners for noncontrolling interest. + References No definition available. + Details
Name: | dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents non-refundable upfront payment, received. + References No definition available. + Details
Name: | dyai_NonrefundableUpfrontPaymentReceived
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents number of performance obligations. + References No definition available. + Details
Name: | dyai_NumberOfPerformanceObligations
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the amount of related-party research and development expense recognized during the period. + References No definition available. + Details
Name: | dyai_ResearchAndDevelopmentExpenseRelatedParty
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents upfront payment payable. + References No definition available. + Details
Name: | dyai_UpfrontPaymentPayable
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_AGlobalFoodIngredientCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_AbicBiolgicalLatoriesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |